Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.66 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379384 | 0.94 | F10 (0.66) | F10DRD4MCHR1SIGMAR1JAK1 | |
| SCHEMBL1381065 | 0.89 | F10 (0.61) | F10DRD4MCHR1SIGMAR1JAK1 | |
| SCHEMBL3799822 | 0.87 | F10 (0.62) | F10DRD4MCHR1SIGMAR1JAK1 | |
| SCHEMBL1381696 | 0.85 | F10 (0.63) | F10DRD4MCHR1SIGMAR1CCR3 | |
| SCHEMBL1383134 | 0.85 | F10 (0.63) | F10DRD4MCHR1SIGMAR1BRD4 | |
| SCHEMBL1381476 | 0.82 | F10 (0.62) | F10DRD4MCHR1SIGMAR1JAK1 | |
| SCHEMBL3794629 | 0.81 | F10 (0.61) | F10PARP1 | |
| SCHEMBL1675257 | 0.80 | F10 (1.00) | F10DRD4 | |
| SCHEMBL5619430 | 0.79 | F10 (0.76) | F10DRD4MCHR1SIGMAR1BRD4 | |
| SCHEMBL1675142 | 0.78 | F10 (0.87) | F10DRD4MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741341-B2 | Benzimidazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-22 | — | — | US | disclosed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | F10 11/4885DRD4 3857/4885MCHR1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.